Autolus Therapeutics (AUTL) Current Deferred Revenue (2021 - 2025)

Autolus Therapeutics (AUTL) has 5 years of Current Deferred Revenue data on file, last reported at $7.6 million in Q3 2025.

• Quarterly Current Deferred Revenue fell 96.26% year-over-year to $7.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $7.6 million (down 96.26% YoY) and the FY2022 annual result came in at $35.0 million, down 25.53% from the prior year.
• Current Deferred Revenue advanced to $7.6 million in Q3 2025, from $2.1 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $203.4 million in Q3 2024 to a low of $2.1 million in Q2 2025.
• A 5-year average of $88.8 million and a median of $51.5 million in 2022 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue soared 168.7% — and 2025, when it tumbled 98.93%.
• Tracing AUTL's Current Deferred Revenue over 5 years: stood at $47.0 million in 2021, then slipped by 25.53% to $35.0 million in 2022, then surged by 302.29% to $140.8 million in 2023, then soared by 44.46% to $203.4 million in 2024, then tumbled by 96.26% to $7.6 million in 2025.
• The last three Current Deferred Revenue figures came in at $7.6 million (Q3 2025), $2.1 million (Q2 2025), and $4.7 million (Q1 2025), per Business Quant data.